Reuters logo
BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
2016年6月6日 / 早上6点32分 / 1 年前

BRIEF-Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX

June 6 (Reuters) - Exelixis Inc and Ipsen

* Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below